LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Evaluation of laboratory assays for anti‐Platelet Factor 4 antibodies after ChAdOx1 nCOV‐19 vaccination

Photo by matnapo from unsplash

Vaccine‐induced immune thrombocytopenia and thrombosis (VITT) following ChAdOx1 nCOV‐19 vaccine has been described, associated with unusual site thrombosis, thrombocytopenia, raised D‐dimer, and high‐titer immunoglobulin‐G (IgG) class anti‐platelet factor 4 (PF4)… Click to show full abstract

Vaccine‐induced immune thrombocytopenia and thrombosis (VITT) following ChAdOx1 nCOV‐19 vaccine has been described, associated with unusual site thrombosis, thrombocytopenia, raised D‐dimer, and high‐titer immunoglobulin‐G (IgG) class anti‐platelet factor 4 (PF4) antibodies. Enzyme‐linked immunosorbent assays (ELISA) have been shown to detect anti‐PF4 in patients with VITT, but chemiluminescence assays do not reliably detect them. ELISA assays are not widely available in diagnostic laboratories, and, globally, very few laboratories perform platelet activation assays.

Keywords: anti platelet; chadox1 ncov; evaluation laboratory; platelet factor; platelet

Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2021

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.